Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 3Lymphoma 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Meningeal Neoplasms 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Fulvestrant 4ribociclib 2palbociclib 2Irinotecan 2Gemcitabine 2venetoclax 1tivozanib 1serabelisib 1sapanisertib 1niraparib 1lorlatinib 1liposomal doxorubicin 1inavolisib 1exemestane 1encorafenib 1cemiplimab 1binimetinib 1abemaciclib 1Taxes 1Tamoxifen 1STX-478 1Paclitaxel 1Metformin 1Lomustine 1Letrozole 1Imlunestrant 1Doxorubicin 1Cetuximab 1Carboplatin 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × sapanisertib × 90 days × Clear all
NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡